Startseite>>Signaling Pathways>> Apoptosis>> Thymidylate Synthase>>Fosifloxuridine nafalbenamide

Fosifloxuridine nafalbenamide (Synonyms: NUC-3373)

Katalog-Nr.GC62645

Fosifloxuridinnafalbenamid (NUC-3373), ein Pyrimidin-Nukleotid-Analogon, ist ein Thymidylat-Synthase-Hemmer. Fosifloxuridinnafalbenamid hat AntikrebsaktivitÄt. Fosifloxuridinnafalbenamid hat das Potenzial, eine Immunantwort des Wirts hervorzurufen und die Immuntherapie zu verbessern.

Products are for research use only. Not for human use. We do not sell to patients.

Fosifloxuridine nafalbenamide Chemische Struktur

Cas No.: 1332837-31-6

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
310,00 $
Auf Lager
5 mg
230,00 $
Auf Lager
10 mg
333,00 $
Auf Lager
25 mg
666,00 $
Auf Lager
50 mg
1.008,00 $
Auf Lager
100 mg
1.512,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunotherapy[1][2].

Fosifloxuridine nafalbenamide induces the release of damage-associated molecular patterns (DAMPs), with increased expression of calreticulin (CRT) at the cell surface and concomitant loss of nuclear nuclear high mobility group box protein 1 (HMGB1)[1].

Fosifloxuridine nafalbenamide exhibits anti-cancer activity in HT-29 nude mouse xenograft models[2].

[1]. Fiona G. McKissock, et al. Abstract 1848: NUC-3373 induces ER stress and the release of damage associated molecular patterns in colorectal cancer cells. Cancer Res August 15 2020 (80) (16 Supplement) 1848.
[2]. Essam A. Ghazaly, et al. Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survival. Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) B46.

Bewertungen

Review for Fosifloxuridine nafalbenamide

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fosifloxuridine nafalbenamide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.